2024-10-26 - Analysis Report
## Amgen Inc (AMGN) Stock Analysis Report

This report provides a comprehensive analysis of Amgen Inc. (AMGN) based on the provided data. 

**1. Performance Comparison:**

* **Company Overview:** Amgen is a biotechnology company that develops, manufactures, and markets pharmaceutical products for serious illnesses. 
* **Cumulative Return:** AMGN's cumulative return stands at 76.54%, lagging behind the S&P 500 (VOO) which has a return of 135.48%.
* **Performance Gap:** The current performance gap is -58.94%, indicating that AMGN has underperformed VOO significantly. This gap is situated at the 27.2 percentile of the historical range, meaning that the current underperformance is within the historical range but relatively towards the lower end.

**2. Recent Price Movement:**

* **Closing Price:**  $315.69 (Last-market: $315.86)
* **Moving Averages:**
    * 5-day moving average: $316.93
    * 20-day moving average: $320.57
    * 60-day moving average: $325.38
* **Analysis:** The stock is currently trading below its 5, 20, and 60-day moving averages, suggesting a potential short-term downtrend.

**3. Technical Indicators:**

* **RSI:** 43.75, indicating a neutral to slightly oversold condition.
* **PPO:** -0.18, suggesting potential weakness in the price momentum.
* **Delta_Previous_Relative_Divergence:** -3.46 (-), suggesting a short-term downward trend.
* **Expected Return:** 0.0%, indicating that over a long-term horizon (2 years or more), the stock is expected to return similar to the S&P 500.
* **Note:** The closing price of $315.86 is not significantly high enough to suggest a sharp rebound or decline. 

**4. Recent Earnings & Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-07 | 1.39 | 8.39 B$ |
| 2024-05-03 | -0.21 | 7.45 B$ |
| 2023-10-31 | 3.23 | 6.90 B$ |
| 2023-08-04 | 2.58 | 6.99 B$ |
| 2024-08-07 | 2.58 | 6.99 B$ |

**Analysis:** The latest earnings report for the quarter ending 2024-08-07 shows that Amgen exceeded EPS estimates.  Revenue also surpassed expectations. However, the previous quarter's EPS was negative, which could be a point of concern.  Overall, recent earnings results are mixed, and further observation of the company's performance and future guidance is crucial. 

**5. News & Recent Issues:**

* **Recent Earnings News:** Please provide the specific earnings news articles (from sources like Shacknews) that have been released within the past 2 days so that a detailed analysis can be provided. 
* **Recent Market Outlook:** Refer to financial news sources like FINBOLD to gather current market sentiment and analyst opinions on AMGN, including performance highlights. This will offer valuable insights into the market's current perspective on Amgen. 

**6. Overall Analysis:**

Amgen Inc. (AMGN) has significantly underperformed the S&P 500, indicating a possible lagging growth strategy. However, its latest earnings report showed a positive surprise, which could be an indicator of a potential upward trend in the future.  Technical indicators suggest a slight weakness in the short term but a neutral to oversold condition in the longer term.  It's crucial to analyze the recently released earnings news, market outlook, and analyst opinions for a comprehensive understanding of AMGN's future prospects. 

**7. Recommendations:**

* **Short-term:** Monitor the stock closely for any signs of a rebound, but cautious approach is advised.
* **Long-term:** With a long-term horizon, AMGN could be a good addition to a diversified portfolio, especially if it can consistently exceed earnings expectations. 
* **Additional Considerations:** 
    * Investigate the specific factors contributing to the recent earnings beat, particularly in light of previous quarters. 
    * Analyze the competitive landscape of the biotechnology sector to gauge AMGN's positioning. 

This analysis provides a starting point for understanding Amgen Inc. (AMGN). For a more comprehensive assessment, it's essential to consider the missing information, conduct further research, and monitor ongoing developments in the company's performance and market conditions. 
